INTRODUCTION 1
Chronic constipation is a functional gastrointestinal disorder characterised by persistently difficult, 2 infrequent or incomplete defaecation that affects approximately 14% of the general population (1, 3 2) . It may be diagnosed using symptom-based diagnostic criteria, such as the Rome IV criteria, 4 according to which a diagnosis is made when two or more of the following symptoms are present 5 for at least a quarter of bowel movements: hard or lumpy stools, straining, a sense of incomplete 6 evacuation, use of manual manoeuvres to pass stool and a sense of anorectal obstruction (1) . 7 Nevertheless, both the general population and some doctors consider various other symptoms 8 important for a diagnosis of constipation, including spending a long time on the toilet without 9 achieving a bowel movement (3, 4) . Furthermore, a large cross-sectional survey in over 3,000 10 members of the general population and doctors revealed differences in the symptoms considered 11 important for a diagnosis of constipation between the general population, general practitioners 12 (GPs) and gastroenterology specialists, and that there was imperfect agreement with the Rome IV 13 criteria, highlighting the difficulties and variability in the diagnosis of chronic constipation (3, 4) .
14 However chronic constipation is diagnosed, it impacts on people's lives, with straining, bloating, 15 abdominal discomfort, abdominal pain and spending a long time on the toilet without a bowel 16 movement being the symptoms most commonly described as being burdensome (3, 5, 6) . A 17 multinational survey has shown a negative correlation between the total number of symptoms of 18 constipation experienced and quality of life, and lower health-related quality of life has been 19 reported by women, as well as by those under psychological stress, such as unemployment (5) . 20 Chronic constipation also impacts on work productivity (6) . 21 The high prevalence of constipation, its chronicity and its impact on quality of life (QoL) 22 contribute to the utilisation of significant healthcare resources. The direct annual cost associated 23 with the management of constipation has been shown to range from $1,912 to $7,522 per year per 24 patient in the United States (7) , whilst in the United Kingdom (UK), there are more than 1 million 25 GP consultations and 69,054 hospital admissions per year where constipation is a diagnosis (8, 9) . 26 Treatment failure for constipation is also associated with a total incremental cost of $2,978, with 27 60% being spent on medical service costs (10) , highlighting the importance of early successful 28 management. 29 4 A variety of different management options exist for constipation, ranging from dietary 1 interventions (e.g. dietary fibre (11) ) and over-the-counter products (e.g. laxatives) to prescription 2 drugs (e.g. serotonin receptor agonists), behavioural interventions (e.g. biofeedback) and different 3 surgical options (12) . However, patient satisfaction is variable; for example, 49% of patients 4 initiating over-the-counter therapies and 58% of patients initiating prescription therapies 5 experience failure of that treatment (10) . Another study reported that almost half of respondents 6 were not completely satisfied with their current constipation treatment (13) . The reasons for patient 7 dissatisfaction were mainly related to efficacy and safety, as well as cost issues and inconsistent 8 results. These findings are supported by another recent web survey demonstrating that 17% of 9 patients with constipation were dissatisfied with laxative use (14) . Taken together, these results 10 show that there is still a substantial unmet need for new effective therapeutic strategies that would 11 be appealing and satisfactory for people with constipation.
12
Over the past decade there has been an increase in research investigating the effect of probiotics 13 in chronic constipation as a potential alternative management strategy. This review aims to assess 14 and present the evidence on the mechanisms of action of probiotics in constipation, their utilisation 15 by patients and health care professionals and the evidence for their effectiveness from clinical 16 trials.
17

POTENTIAL MECHANISMS OF ACTION OF PROBIOTICS IN CONSTIPATION
18
Probiotics are "live microorganisms that, when administered in adequate amounts, confer a health 19 benefit on the host" (15) . There are several mechanisms of action of probiotics relevant to 20 constipation, including modulation of the gut microbiota and fermentation, nervous system and 21 immune system, as shown in Figure 1 (16) . 22 Several studies have demonstrated differences in the gut microbiota composition between people 23 with and without constipation (16) , with a decreased concentration of bifidobacteria and lactobacilli, 24 as well as increased numbers of Bacteroidetes, identified in people with constipation (16) (17) (18) . Faecal 25 microbiota composition has been shown to correlate with colonic transit time, while the colonic 26 mucosal microbiota composition correlates with constipation status (18) . Although the impact of 27 probiotics on the microbiota in constipation is not well understood, a small number of trials have 28 demonstrated significant changes in gut microbiota composition following probiotic 29 supplementation (16) . For example, supplementation of Bifidobacterium lactis GCL2505 or 30 5 Lactobacillus casei Shirota increased concentration of bifidobacteria, however B. lactis NCC2818 1 and VSL#3, a multi-strain probiotic, had no impact on gut microbiota composition (19) (20) (21) (22) . These 2 results suggest that administration of probiotics may impact on certain microbiota components, 3 but it is yet to be determined what impact this change has on constipation, and whether effects are 4 mediated through microbiota modification or other mechanisms.
5
It is likely that it is the physiologically active substances produced by the gut microbiota that have 6 an impact on motility, rather than the microbiota per se. Metabolic byproducts of the microbiota 7 that might contribute to a change in gut function in response to probiotic supplementation include 8 short-chain fatty acids (SCFA), which are primary end-products of fermentation of non-digestible 9 food components including carbohydrates ( Figure 1) (23) . In vitro and ex vivo experiments have 10 shown that SCFA may affect gut motility by stimulating mucosal receptors connecting to enteric 11 or vagal nerves (24) , acting directly on colonic smooth muscle (25, 26) or via increasing intraluminal 12 serotonin concentration, an excitatory neurotransmitter (27) . When investigating the impact of 13 probiotics on SCFA concentrations in people with constipation, several human studies show 14 significant changes (21, (28) (29) (30) , however others show little impact (31, 32) . These results may be 15 attributed to the different strains used in the studies and because stool, rather than luminal SCFA 16 concentrations are measured, which is not predictive of SCFA production in the proximal colon 17 (33) .
18
The colonic mucus may also play a role in regulating gut motility as it acts as a lubricant and 19 facilitates stool passage (34) , while bile acids may affect motility through luminal electrolyte and 20 water transport regulation as demonstrated by in vitro and animal studies (35, 36) . However, there is 21 currently little evidence that probiotics affect bile acid metabolism or mucin excretion in humans 22 (37) (38) (39) . 23 Modulation of microbiota-gut-brain interactions with probiotics has been demonstrated in healthy 24 people (40) , while L. reuteri has been shown to increase the excitability of myenteric neurons in rats 25 and interact with the gut-brain axis via alterations on afferent sensory nerves that affect gut 26 motility, indicating that that probiotics do impact on the enteric nervous system (41, 42) . Hence, 27 probiotic-mediated modulation of microbiota-gut-brain interactions has been proposed as a 28 potential novel therapeutic tool for the treatment of gut motility disorders, including constipation; 29 however, there are no human studies in constipation.
6
Lastly, there is emerging evidence of an inflammatory response in some people with constipation 1 (43) , which may alter enteric sensory and motor function (44) . A potential impact of the probiotics 2 on inflammatory response may, therefore, potentially affect gut motility regulation and, hence, 3 constipation. Indeed, certain probiotics modulate the mucosal immune barrier or systemic immune 4 barrier, and normalise dysmotility (45, 46) . For example, L. paracasei has been shown to produce 5 antagonistic metabolites and antioxidants, such as glutathionine, to stimulate the immune system 6 in vitro (47) , while people who consumed B. lactis for 6 weeks had significantly higher interferon-7 alpha, and polymorphonuclear cell phagocytic capacity compared to placebo (48) . Hence, probiotics 8 may have beneficial effects with regard to some components of the immune system that could 9 potentially influence gut motility, but the effect on their immune regulation in constipation has yet 10 to be extensively investigated.
11
Therefore, there is evidence that certain probiotics may confer beneficial effects on constipation 12 via their impact on the gut microbiota and fermentation, the enteric and central nervous system, 13 and the immune system. However, the vast majority of evidence originates from in vitro and 14 animal studies and thus the mechanisms of action of probiotics in humans remain unclear and 15 warrants further research.
16
EFFECTIVENESS OF PROBIOTICS IN CONSTIPATION
17
The impact of probiotics on gut transit time (GTT) and the management of constipation has been 18 investigated by many randomised controlled trials (RCTs), as well as in systematic reviews and 19 meta-analyses, and these have been performed mainly for the probiotics bifidobacteria and 20 lactobacilli.
21
In terms of bifidobacteria, one study that investigated the effect of B. lactis DN-173010 revealed 22 significant improvement in stool consistency, as well as an increase in stool frequency by +1.5 23 bowel movements/week, compared to placebo in 135 women with chronic constipation (49) .
24
Another triple-blind, three arm, placebo-controlled RCT that compared consumption of two 25 different doses of B. lactis HN019 and placebo for two weeks in 88 people with constipation 26 showed that the probiotic significantly decreased whole GTT in a dose-dependent manner; the 27 high dose probiotic group experienced a reduction of -28 h in whole GTT compared to -19 h 28 decrease and +1 h increase in the low dose and placebo group respectively (p<0.001) (50) . 29 Interestingly, a subsequent double-blind RCT that investigated the effect of the same B. lactis 30 7 HN019 strain in 228 people with chronic constipation showed no significant differences in whole 1 GTT, gut symptoms, constipation-related quality of life, stool frequency or stool consistency 2 between the probiotic and placebo groups (51) . Similarly, a double-blind placebo-controlled RCT 3 investigating the effect of B. lactis NCC2818 in 75 people with chronic constipation showed no 4 significant differences in whole and regional GTT, stool frequency, stool consistency, gut 5 symptoms, quality of life, and stool microbiota composition (22) . Therefore, differing results have 6 been demonstrated even for different B. lactis strains, highlighting the effects of probiotics may 7 be strain-specific. 8 In terms of lactobacilli, an RCT in 20 people with chronic constipation also showed a significant 9 increase in stool frequency compared to controls following L. reuteri DSM 17938 administration, 10 but no improvement in stool consistency (52) . L. casei Shirota has been shown to decrease the 11 occurrence of hard stool compared to placebo in chronic constipation, while flatulence and 12 bloating were unaffected (53) . It is worth noting that both the probiotic and placebo groups 13 experienced an increase in stool frequency by +3 and +2 bowel movements/week compared to 14 baseline, respectively, even though this difference between the two groups was significant (53) . 15 Interestingly, an increase in stool frequency was also observed at baseline in both groups compared 16 to the initial assessment which had taken place two weeks prior to baseline, indicating a possible 17 placebo effect (53) . Another RCT in 90 people with chronic constipation showed that four weeks of 18 L. casei Shirota administration did not improve stool consistency and quantity compared to 19 placebo; however, a significant within-group improvement was seen following the probiotic (54) .
20
A double-blind, 3-arm RCT in 300 people with hard stools (but not specifically with a diagnosis 21 of constipation) reported a significant improvement in stool frequency and consistency, ease of 22 expulsion, sense of complete evacuation and bloating following the administration of L. plantarum 23 LMG P-21021 and B. breve DSM 16604, or B. lactis LMG P-21384, compared to placebo (55) .
24
Six systematic reviews have investigated the effect of probiotics in outcomes relevant to chronic 25 constipation, summarised in Table 1 . Of these systematic reviews, one did not synthesize data into 26 a meta-analysis due to studies not being sufficiently similar and of sufficient quality (56) , and 27 another (57) is similar to a subsequent systematic review published a year later by the same group (58) 28 and therefore both are summarised in the table but not discussed here. The findings of the 29 remaining four systematic reviews are summarised below. Firstly, a systematic review and meta-analysis of 11 RCTs (n=464) that assessed the effect of 1 probiotics (including B. lactis, B. longum, L. casei and L. rhamnosus with doses ranging from 2 0.48×10 9 to 97.5×10 9 CFU/d and treatment duration from 10 to 28 days) on gut transit time in both 3 healthy and constipated people was published in 2013 and revealed a significant decrease in GTT 4 (Standard Mean Difference, SMD: 0.40, p<0.001) following probiotic (median period of 5 consumption: 18 days), with the presence of constipation being predictive of greater GTT 6 reductions (59) ; greater reductions in GTT were seen in people with constipation compared to those 7 without constipation in a further sub-group analysis of 7 studies (SMD: 0.59, p=0.01) (59) . 8 Secondly, in 2014, a systematic review and meta-analysis of two RCTs (n=110) that administered 9 6.5×10 9 CFU/d L. casei Shirota for 3 weeks or 1.25×10 9 CFU/d B. lactis for 2 weeks showed a 10 significant increase in stool frequency (mean difference: +1.5 bowel movements per week, 95% 11 CI: 1.0-2.0 bowel movements per week), but there was no significant difference in the 12 dichotomous outcome of failure to respond to therapy compared to placebo (RR: 0.29, 95% CI 13 0.07-1.12) (60) . 2.5 h) and increased stool frequency by +1.3 bowel movements/week (95% CI: 0.7, 1.9 bowel 17 movements/week) (61) . The dose of probiotics used in the individual studies ranged from 10 8 to 18 3×10 10 CFU/d and the treatment period varied from 2 to 8 weeks. Importantly, the sensitivity 19 analysis showed species-and strain-specific effects of probiotics as stool frequency was 20 significantly higher following B. lactis species (mean difference: +1.5 bowel movements/week; 21 95% CI: 0.7, 2.3 bowel movements/week), but not following L. casei Shirota (mean difference: -22 0.2 bowel movements/week; 95% CI: -0.8, 0.9 bowel movements/week) (61) . Similarly, stool 23 consistency was significantly improved following B. lactis administration, but not for L. casei 24 Shirota (61) . 25 Fourthly, a recent systematic review and meta-analysis of 21 RCTs (n=2,656) showed that 26 probiotics significantly reduced gut transit time (SMD: 0.65, p<0.001) in people with constipation, 27 and the mean difference in stool frequency was +0.83 bowel movements/week (p<0.001); 28 however, after adjusting for publication bias, the difference in stool frequency was reduced to 0.3 29 bowel movements per week (95% CI -0.01 to 0.62 bowel movements per week) which was not 30 9 statistically significant (58) . The dose of probiotics used in the individual studies ranged from 1 0.1×10 9 to 30×10 9 CFU/d and the treatment period varied from 7 to 84 days. In addition, the 2 probiotic products used in some of the studies also contained additional ingredients (e.g. psyllium, 3 inulin and fructo-oligosaccharides) that did not allow for the effect of the probiotic alone to be 4 isolated (58) . This, in addition to the increased heterogeneity among the studies, denotes that caution 5 is needed in interpreting the results. 6 The interpretation of these findings from systematic reviews and meta-analyses is challenging due 7 to high heterogeneity and risk of bias of the individual studies, and because species-and strain-8 specific effects have been identified. Firstly, although meta-analyses synthesize data from many 9 trials in order to improve the statistical power to detect the direction, size and consistency of a 10 clinical effect, they cannot overcome limitations in the design of individual trials. Secondly, 11 different probiotic species and strains have different microbiological and physiological 12 characteristics, and therefore synthesizing data from different probiotics and different doses is 13 questionable (62) . Despite these challenges, the results provide cautious optimism for the 14 recommendation of specific probiotic strains in the management of chronic constipation. Further 15 adequately powered RCTs using standardized outcome measures are needed to determine which 16 species/strains, doses and duration of probiotics are efficacious.
17
USE OF PROBIOTICS IN CONSTIPATION
18
Given the impact of constipation on quality of life, and the effectiveness of certain probiotics in 19 improving constipation-related symptoms, there is increasing interest in using probiotics as a 20 therapeutic option.
21
A survey in 269 patients attending outpatient gastroenterology clinics identified that 44% used 22 complementary and alternative medicines (CAM), with constipation being the most cited symptom 23 to be addressed, and probiotics being the most common CAM used (63) .
24
The prevalence of probiotic use in constipation was also confirmed in a recent large cross-sectional 25 study in 2,557 members of the UK general population, of whom 1,623 had self-reported 26 constipation (64) . This study revealed that the strongest predictors for probiotic use in the general 27 population was having constipation, although this was a population selected for such symptoms 28 (64) . It was also shown that 60% of the general population with constipation had previously used or 29 10 were currently using probiotics, compared to 51% of those without constipation (p<0.001). In fact, 1 self-reported constipation was associated with a 4.7 greater likelihood of current probiotic use 2 (OR: 4.7, 95% CI 3.8-5.7, p<0.001). In those with self-reported constipation, significant predictors 3 of probiotic use for either general health or gut health specifically was 'believing probiotics have 4 been tested in research for their effectiveness in constipation' (OR 2.06, 95% CI 1.56-2.72, 5 p<0.001), having a university degree (OR: 1.76, 95% CI 1.32-2.35, p<0.001), being older (OR: 6 1.02, 95% CI 1.01-1.03, p<0.001), and being female (OR: 0.54, 95% CI 0.35-0.81, p=0.003) (64) .
7
The finding that females are more likely to use probiotics than males may be explained by the fact 8 that constipated women report significantly worse quality of life compared to constipated men (5) . 9 Therefore, women may be more likely to seek additional or alternative treatments for their 10 symptoms than men. Indeed, a previous study has confirmed that constipated subjects seeking 11 medical care are most likely to be females (65) .
12
In terms of the recommendation of probiotics by doctors, probiotics seem to be commonly 13 recommended for the management of gastrointestinal disorders, such as chronic diarrhoea and 14 irritable bowel syndrome (66) . A UK survey of over 1500 primary care health professionals (e.g.
15
GPs, dietitians, nurses) showed that 78% of GPs advise probiotic use for their patients, with 16 constipation being the 5 th most common condition for which they are recommended (67) . However, 17 a recent survey in 411 GPs and 365 gastroenterology specialists showed that 66% of GPs and 74% 18 of gastroenterology specialists do not recommend them for constipation (64) . A possible reason for 19 this might be the perceived lack of research evidence in this area. Indeed, only 35% of GPs and 20 43% of GI specialists believe there is evidence for probiotic use in constipation (64) , despite existing 21 evidence from RCTs showing that certain probiotic strains may improve constipation-related 22 symptoms (58, 61) . Interestingly, the gastroenterologist specialists who believed there is evidence for 23 probiotics in constipation thought probiotics were more effective for the management of 24 constipation, compared with those who did not believe there is evidence (64) . Belief in the existence 25 of scientific evidence for probiotics among doctors is therefore likely an influencer on the belief 26 in their impact on symptoms and on their behaviour in terms of recommending them to patients. DN 114 001 (Actimel) and L. casei Shirota (Yakult) are the probiotics most commonly used by 1 the general population with constipation (64) . This is in agreement with the probiotic products that 2 patients with inflammatory bowel disease also choose to use (68) . Although there are a few reports 3 showing beneficial results of some of these strains in constipation, these studies have various 4 limitations, such as small sample sizes or the absence of objective outcomes (20, 54, 69, 70) .
5
Interestingly, no study has been previously published on the effect of Actimel (L. casei DN 114 6 001) on constipation. Therefore, the choice of the probiotic product used by the general population 7 and doctors is not necessarily driven by the current scientific evidence available, but could be 8 influenced by factors such as availability or product advertising.
9
Indeed, TV adverts were the most common source of information for probiotics in gut health, 10 followed by family, friends and the internet in general (Figure 2) (64) . This is mostly in agreement 11 with the findings of a previous survey that showed that commercial advertising was the most 12 common source of information for probiotic use in patients with inflammatory bowel disease, 13 followed by family and friends, and healthcare professionals (68) . Similarly, another survey showed 14 that the most common sources of information for the use of CAM (including probiotics) in 15 gastrointestinal conditions were family, newspapers, magazines, the internet and friends (63) .
16
Taken together, the evidence shows that more people with self-reported constipation use probiotics 17 compared to those without self-reported constipation, however, the vast majority of GPs and 18 gastroenterologist specialists do not recommend them for constipation. This could possibly be 19 explained by the fact that the vast majority of doctors do not believe probiotics have been tested 20 in research studies for their effect in constipation.
21
CONCLUSION
22
The evidence on the effectiveness of probiotics remains varied, with certain strains exhibiting 23 beneficial effects, while others show little effect. This highlights that the effects of probiotics may 24 be strain-specific and that each strain needs to be tested in a high-quality RCT using standardized 25 and validated assessment techniques in order to be able to devise clinical recommendations 26 regarding probiotic use in constipation in the future. This, in combination with the increased 27 probiotic usage in constipation, indicates a need to clearly communicate and raise the public's 28 awareness on the current state of the evidence on probiotics and constipation. Education of health 29 care professionals is also required on both the strain-specificity of the effects of probiotics, but 30 12 also on the degree of probiotic usage by the public; this may encourage health care professionals 1 to query about probiotics and discuss their use with patients and, therefore, educate them on the 2 uncertainty in the available evidence. the byproducts of which interact with pattern-recognition receptors, such as TLRs, as well as with 5 dendritic cells. SCFAs increase intestinal regulatory T cells, which limit intestinal inflammation, 6 by reducing histone deacetylase 9 gene expression (71) . The gastrointestinal microbiota regulates 5-7 HT production by elevating its synthesis by host enterochromaffin cells via the release of 8 metabolites, such as deoxycholate, which activates TGR5, expressed by enterochromaffin cells (72) . 9 5-HT is also released from enterochromaffin cells in response to SCFAs produced by the 10 gastrointestinal microbiota and stimulates 5-HT3 receptors located on the vagal afferent fibers, 11 resulting in muscle contractions (27) . Gases produced by the gastrointestinal microbiota seem to 12 affect gut motility via the enteric nervous system, rather than the brain-gut axis; however, the exact 13 mechanisms are still unknown (73) . Moreover, the gastrointestinal microbiota is key to the 14 development of the enteric nervous system, which is the primary regulator of gut motility, and 15 certain bacteria are known to produce 5-HT. Calcitonin gene-related protein, a sensory 16 neuropeptide, modulates dendritic cell function and may signal the presence of gastrointestinal 17 microbiota to the brain (74) . Components of the gastrointestinal microbiota also act via intestinal 18 19 dendritic cells to influence the inflammatory process (75) . TLRs signaling controls the enteric 1 nervous system structure and neuromuscular function and hence motility (76) . Bile acids activate 2 TGR5 expressed by enterochromaffin cells and myenteric neurons and release 5-HT and calcitonin 3 genre-related peptide. Furthermore, probiotics appear to interact with the gut-brain axis via the 4 modulation of afferent sensory nerves that influence gut motility. CH4, methane; H 2 , hydrogen; 5 TGR5, a G protein-coupled receptor; TLR, toll-like receptor; 5-HT, 5-hydroxytryptamine; 5-HT3, 6 5-hydroxytryptamine type 3. Taken with permission from Dimidi et al. 2017 (16) . on an online survey in 346 people with self-reported constipation. GP, general practitioner (4.6% 4 did not report a source of information for probiotic use and this is not depicted in the figure).
5
Adapted from data presented in Dimidi et al. 2019 (64) . Table 1 : Systematic reviews and meta-analyses of randomised controlled trials investigating the effect of probiotics on gut transit time and constipation in adults.
Study
Review Characteristics of studies included in the systematic reviews Number of studies and subjects 
